The biotech and Gavi will cancel their existing supply deal for vaccines based on the original COVID-19 strain, which has led to the supply of nearly 70 million doses to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries, in addition to Moderna facilitating the donation of more than 100 million doses to these countries.
“Gavi and our COVAX partners have been pivotal in ensuring the global supply of COVID-19 vaccines, leading the largest and most rapid vaccine rollout in history,” said Stéphane Bancel, chief executive officer of Moderna.
